Home/Filings/4/0001209191-12-053796
4//SEC Filing

Kelly Lisa 4

Accession 0001209191-12-053796

CIK 0000875320other

Filed

Nov 18, 7:00 PM ET

Accepted

Nov 19, 4:35 PM ET

Size

11.2 KB

Accession

0001209191-12-053796

Insider Transaction Report

Form 4
Period: 2012-11-15
Kelly Lisa
SVP, Human Resources
Transactions
  • Sale

    Common Stock

    2012-11-15$40.59/sh355$14,40917,249 total
  • Sale

    Common Stock

    2012-11-16$41.28/sh2,033$83,92215,216 total
Holdings
  • Common Stock

    (indirect: By 401(k))
    1,959
Footnotes (4)
  • [F1]Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1.
  • [F2]Open market sales reported on this line occurred at a weighted average price of $40.59 (range $40.34 to $41.23).
  • [F3]Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  • [F4]Open market sales reported on this line occurred at a weighted average price of $41.28 (range $41.01 to $41.82).

Issuer

VERTEX PHARMACEUTICALS INC / MA

CIK 0000875320

Entity typeother

Related Parties

1
  • filerCIK 0001349077

Filing Metadata

Form type
4
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 4:35 PM ET
Size
11.2 KB